Purpose The purpose of this study was to compare the use of fluorine-18-fluorodeoxyglucose ( 18 F-FDG) PET with computed tomography (CT) and dynamic contrast-enhanced (DCE) MRI to predict prognosis and monitor treatment in malignant pleural mesothelioma. F-FDG PET/CT (maximum standardized uptake value, metabolic tumour volume and total lesion glycolysis) and DCE-MRI (integrated area under the first 90s of the curve and washout slope) were compared with overall survival (OS) using Kaplan-Meier and Cox regression analyses, and changes in imaging measurements were compared with disease progression.
Introduction
Malignant pleural mesothelioma (MPM) is caused by exposure to asbestos dust. There is a long latency period, typically 30-40 years, between exposure and development of the disease, so incidence continues to rise long after asbestos use has finished. Death rates in Great Britain have continued to increase [1] , from 24.6 per million for men and 3.3 per million for women in 1984-1986 to 68.2 and 12.7 deaths per million in 2011-2013; death rates are expected to level off over the next decade. Patients with MPM have a life expectancy of only 9-14 months following diagnosis [2] . Chemotherapy with pemetrexed and cisplatin [3] has been shown to have a significant survival benefit.
The South West Area Mesothelioma and Pemetrexed Trial (SWAMP) [4] was designed to examine the use of imaging with fluorine-18-fluorodeoxyglucose ( 18 F-FDG) PET/CT to predict overall survival (OS) from baseline imaging, and to correlate changes in PET/CT with progression-free survival. Dynamic contrast-enhanced (DCE) MRI was carried out on patients on the same day as PET/CT, but not used as a primary or secondary outcome measure owing to the lack of established evidence to define responders and nonresponders. The aim of this substudy is to compare 18 F-FDG PET/CT and DCE-MRI parameters at baseline, in comparison with OS, and compare change with radiological progression.
Patients and methods

Patients
In all, 73 patients with biopsy-proven MPM were recruited over 3 years from 2008 to 2011 at seven centres under the SWAMP trial [4] . Ethical and regulatory approval for the study was obtained before recruitment commenced (UK REC reference: 08/H0102/46), and all subjects signed a written informed consent form. The trial was registered in the UK national portfolio (UKCRN ID: 8450). Inclusion criteria were a life expectancy exceeding 3 months, and no previous debulking surgery or other radical therapy.
All patients were offered chemotherapy with pemetrexed and cisplatin or carboplatin by the oncologist responsible for their clinical care. A total of 58 patients had chemotherapy, whereas 15 patients who declined chemotherapy received best supportive care. OS was measured from recruitment until death or until the study closed -12 months after the last patients were recruited. All patients were offered imaging at study entry and after 6 weeks, following two cycles of chemotherapy.
Imaging
18
F-FDG PET/CT scans and DCE-MRI scans were conducted in the same half-day appointment at a single imaging centre; all patients were offered both. The DCE-MRI scan was undertaken before the 18 F-FDG PET/CT to minimise radiation exposure of clinical staff. Trial scans were stored without direct identification to the patient and results were not accessible to oncologists responsible for their care.
Progression was determined from CT scans carried out separately, but scored centrally, using the modified RECIST criteria [5] .
DCE-MRI
Patients were screened for contraindications to MRI scanning by both the clinical trials team and experienced radiographers, and imaged on a 1-Tesla High Field Open System (Philips Medical Systems, Best, The Netherlands).
Patients were scanned using a fat-saturated T1W axial sequence covering the entire lungs from just above the apices to just below the bases -usually achieved with around 70 contiguous slices of 4 mm thickness. There were 20 phases -1 precontrast and 19 postcontrast. The frame time was 45-55 s, depending on the imaging field of view. A volume of 15 ml of gadolinium-based contrast (gadoteric acid) was injected at a rate of 1 ml/s.
PET/CT acquisition
PET/CT scans were performed using a Gemini-GXL scanner (Philips Medical Systems) with Brilliance 16 slice CT. Patients were nil by mouth for 6 h before the injection of 400 MBq 18 F-FDG. Blood sugar was checked to be within normal range before injection. A 90 min uptake period was allowed. PET images were corrected for photon attenuation using the CT scan and normalized by body weight. The QA of the PET/CT scanner was carried out according to best accepted practice in the UK.
DCE-MRI and curve analysis
A method for region of interest (ROI) definition was developed, based on Giesel et al. [6, 7] A similar method has been described for a study of Zoledronic acid in pleural disease [8] . The tumour was identified on the T1 image (Fig. 1a) , taking account of the enhancement image by a consensus of two radiologists experienced in DCE-MRI analysis. A freehand ROI was defined on a single slice around the pleural tumour at the level with the largest clearly definable area of tumour on the Philips Medical Systems workstation, taking care to exclude normal lung. A graph of image intensity against frame was generated for each ROI and image sequence (Fig. 1b) .
The curve data were transferred as a text file from the Philips Medical Systems workstation to a spreadsheet programme (Microsoft Excel). The time from baseline image to the first enhanced image varied, and thus t = 0 was taken to be one frame length before the first enhancement point.
From the percentage enhancement-time curve, the integrated area under curve in the first 90s (IAUC90) and the washout slope (change in percent enhancement/min) from 4 to 8 min were calculated. The area under the curve was calculated using the trapezium rule, and the change between data points was assumed to be linear for calculations of area under the curve. The washout slope was further defined as being type 1 if the enhancement increased by at least 1% from 4 to 8 min (slope > 0.25%/min), type 3 if the enhancement decreased by at least 1% from 4-8 min (slope < − 0.25%/min) and type 2 if the enhancement neither increased nor decreased (slope between − 0.25 and + 0.25%/min).
F-FDG PET/CT image analysis
The tumour volume of interest was defined as all voxels with a standardised uptake value (SUV) greater than 2.5 [9] within both lungs; this could include discontiguous volumes in diffuse disease. This was edited using tools within MIM software, version 5 (MIMvista Corp., Cleveland, Ohio, USA), to remove physiological areas of uptake such as myocardium (Fig. 2) . The following parameters were derived from the images: maximum standardized uptake value (SUV max ), metabolic tumour volume (MTV) and total lesion glycolysis (TLG = MTV × mean SUV).
Statistical analysis
Statistics were calculated using the statistical package R [10] . Baseline comparisons between DCE-MRI and PET/ CT measurements were carried out on all patients, whereas survival analysis and comparison with progression-free survival were carried out on chemotherapy patients. Kaplan-Meier estimates for OS were generated using the survival package of R [11] . Significance of differences in Kaplan-Meier analysis was tested using the log-rank test. Kaplan-Meier statistics were calculated comparing values above and below group median for TLG, SUV max , MTV and IAUC90, and comparing slope types for DCE-MRI washout curves. A P value of 0.05 was taken to be significant, and multiple comparisons were corrected for using the Holm-Bonferroni correction.
Results
Patients
In all, 73 patients were recruited between September 2008 and December 2011; 58 were recruited to the chemotherapy arm and 15 to the comparator arm. Of these, 65 had baseline PET/CT (51 chemotherapy arm; four withdrew from the trial, three were unable to tolerate scans, and one was too unwell) and 61 had baseline DCE-MRI scans available (50 chemotherapy arm; four sets of data were unable to be analysed for technical reasons). A total of 54 patients had follow-up PET/CT (41 chemotherapy arm; four had problems with chemotherapy, one was unable to tolerate scans, three were too unwell, one died, two corrupted scans) and 47 had follow-up DCE-MRI available for analysis (37 chemotherapy arm; seven studies were unable to be analysed). Median follow-up time was 892 days [interquartile range (IQR): 605-1144 days]; 12 patients were alive at the time of analysis. Patient characteristics are shown in Table 1 .
Clinical outcomes
Median survival from consent to death in the chemotherapy group was 368 days (IQR: 195-526) and in the comparator group it was 325 days (IQR: 176-458) equating to 12.3 and 10.8 months, respectively (P = 0.40). The number of chemotherapy cycles delivered was determined by oncologists using standard clinical assessment without access to serum biomarkers or PET/ CT results. In all, 87% of patients in the chemotherapy group received two or more cycles, 64% received four or more cycles and 36% received six cycles. Histological subtype was a strong independent predictor of survival, with epithelioid histology associated with a median survival of 456 (IQR: 303-609) days compared with 197 (IQR: 155-239) days (P < 0.001) in patients with nonepithelioid histology.
Comparison between PET/CT and DCE-MRI Baseline measurements from PET/CT and DCE-MRI were compared with each other for all patients, treated and control groups. From PET/CT, SUV max , TLG and MTV were correlated (P < 0.0001) and from DCE-MRI IAUC90 and washout slope were correlated (P = 0.003). There were no significant correlations of SUV max with IAUC90 ( Fig. 3 , r = 0.25, P = 0.055) or washout slope (Fig. 4 , r = − 0.17, P = 0.19), MTV with IAUC90 (r = 0.12, P = 0.36) or washout slope (r = − 0.14, P = 0.30), or TLG with IAUC90 (r = 0.15, P = 0.27) or washout slope (r = − 0.16, P = 0.22). There were no significant correlations when subgroups were tested with or without pleurodesis, or with epithelioid or nonepithelioid histology.
Comparison with overall survival
Baseline measurements from PET/CT and DCE-MRI were compared with OS for treated patients.
From univariate Cox regression analysis, the only significant factors were histology and SUV max , and MTV and TLG from PET/CT (Table 2 ). In multivariate analysis, if histology was included no other factors were Comparison of integrated area under the first 90s of the DCE-MRI enhancement-time curve (IAUC90) with the SUV max . DCE, dynamic contrast-enhanced; SUV max , maximum standardized uptake value.
significant; if histology was excluded then SUV max was most significant.
All PET/CT measurements showed a significant relationship with OS by Kaplan-Meier analysis, comparing values above and below median. SUV max above median (10.6) had OS of 268 (177-481) days and below median 525 (270-735) days (P = 0.001) (Fig. 5) ; MTV above median (460 ml) had median OS of 264 (IQR: 177-439) days, and below median MTV had median OS of 562 (274-735) days (P = 0.0001); and TLG above median (1806 SUV-ml) had OS of 264 (177-439) days and below median 562 (274-735) days (P = 0.0001).
For DCE-MRI, baseline IAUC90 was not significantly related to OS (Fig. 6) ; IAUC90 above median (88%-min) gave median OS of 270 (IQR: 232-507) days, below median 506 (250-735) days (P = 0.07). Washout slope was significantly related to OS ( Fig. 7) : type 1 (n = 13) median OS of 562 days (IQR: 481-872) days, type 2 (n = 6) median OS of 256 days (IQR: 104-498 days) and type 3 (n = 31) median OS of 274 (204-525) days (P = 0.023).
Combining PET/CT SUV max and DCE-MRI washout slope gave additional information (Table 3 and Fig. 8 ).
Those with SUV max less than 10.6 and type 1 curves had the longest survival, median OS of 735 days, SUV max less than 10.6 and type 2 or 3 curves had median OS of 426 and 401 days, whereas patients with SUV max less than 10.6 had median OS of 312, 130 and 268 days for type 1, 2 and 3 curves, respectively (P = 0.009). Numbers in each group were too small to calculate confidence intervals for OS.
There was no significant difference in OS between those who had and had not had pleurodesis.
Comparison with progression from CT
Changes in PET/CT (SUV max , MTV and TLG) and DCE-MRI (IAUC90, washout slope) were compared with progression-free survival at 8 weeks (Table 4 ), 15 weeks (Table 5 ) and 12 months (Table 6 ). Change in washout slope at 7-9 weeks and MTV and TLG at 9 months were significant at the P value less than 0.05 level, although correcting for multiple comparisons these were not significant (P < 0.003 required for 15 comparisons).
Discussion
MRI of the lungs is difficult owing to breathing-related motion artefact. As a consequence of this, the slice on which the analysis is carried out moves relative to the tumour between time points, and thus the enhancementtime curves were somewhat noisy. However, the advantage of using the area under the curve and the washout slope is that the effect of movement on these measurements should be limited, as movement will effectively be smoothed out. PET/CT is also subject to movement, which can be seen from the mismatch between the PET and the CT particularly at the lung bases. This will cause the uptake to be somewhat smoothed, with a potential reduction in SUV max . This should have limited effect on Comparison of washout rate (%/min) of the DCE-MRI enhancementtime curve with the SUV max . DCE, dynamic contrast-enhanced; SUV max , maximum standardized uptake value. the volumetric measures in most case, unless the uptake is close to the threshold. A fixed SUV threshold was used to analyse PET images, as this is a method that is widely available, and does not require specialised software. The other method most widely used, a threshold at around 40% of maximum, would not be appropriate for diffuse tumour, as this is a method that has been validated for discrete solid tumours. In some cases there was visible tumour on PET/CT, which was below the threshold of SUV =2.5 and thus was not included in the MTV. Kaplan-Meier analysis, chemotherapy patients, for SUV max with overall survival. 18 F-FDG, fluorine-18-fluorodeoxyglucose; SUV max , maximum standardized uptake value. Kaplan-Meier analysis, chemotherapy patients, for IAUC90 with overall survival. DCE, dynamic contrast-enhanced; IAUC90, integrated area under the first 90s of the curve.
However, these cases would have low 18 F-FDG uptake measured, which would be correlated with relatively long survival times.
The analysis used for PET was fully three-dimensional (3D) and took account of all active tumour throughout both lungs. On the other hand, the method for MRI was based on analysis of data from a single slice through the largest volume of tumour. The largest tumour volumes corresponded for MRI and PET; however, the SUV max did not necessarily lie at the same point as the centre of the MRI ROI, although it often would have done. It would clearly be preferable to have used more comparable 3D analysis methods in both cases. However, the different measurements from PET/CT, SUV max , MTV and TLG were strongly correlated, suggesting that the overall tumour function can be measured using a measurement of uptake at a single voxel. This suggests that the difference between two-dimensional and 3D analysis may not be too significant in this case. There was also no attempt to register studies before and after treatment, and image analysis was performed separately for pretreatment and post-treatment studies.
Probably of most importance is the different physiological and pathological meaning of the results. DCE-MRI is a measure of perfusion, whereas 18 F-FDG PET/ CT is a measure of metabolism. The results indicate that more active tumour tends to have higher perfusion, but that the metabolism from SUV max or TLG is more significantly related to OS. SUV max from PET/CT and curve shape from DCE-MRI were combined (Table 3) ; in this case, SUV max was the most significant factor, as patients with SUV max less than median (10.6) had longer survival than those with SUV max more than median for all DCE-MRI curve shapes, but within this curve shape 1 generally gave longer survival than curve shapes 2 or 3.
A number of previous studies [9, [12] [13] [14] [15] [16] [17] [18] [19] , mostly retrospective and observational, have considered the relationship between survival and PET measurements at baseline. Of these, eight studies [12] [13] [14] [15] [16] [17] [18] [19] with a total of 594 patients found that high SUV max or TLG at baseline indicated worse survival, and one with 41 patients [9] found no relationship. Three studies have considered percentage change in SUV max , TLG and MTV after chemotherapy; two [9, 20] with a total of 64 patients found that a percentage reduction in TLG was indicative of better OS, whereas one [19] with 131 patients found a percentage reduction in SUV max was related to longer Kaplan-Meier analysis, chemotherapy patients, for washout curve shape with overall survival. CT, computed tomography; DCE, dynamic contrast-enhanced; LCL, lower confidence limit; NA, not available; OS, overall survival; SUV max , maximum standardized uptake value; UCL, upper confidence limit.
OS. Prior pleurodesis has also been indicated as an issue, causing raised SUV max in some studies [21, 22] , but this was not found in our study.
Previous work on the use of DCE-MRI in MPM used a pharmacokinetic modelling method to analyse studies on 19 patients with epithelioid histology, and showed longer OS for patients with a lower redistribution rate constant [6, 7] , although this was not significant.
The utility of DCE-MRI in MPM with enhancementtime curves and curve-based analysis is well established in breast cancer trials [23] , whereas the curve shape and particularly the washout slope are used in clinical assessment of DCE-MRI studies in breast cancer [24] . Currently, DCE-MRI is not used in routine clinical practice in evaluating lung or pleural malignancy. It has not been extended into clinical practice partly owing to technical difficulties of respiration and the complex morphological characteristics of the lesions. In this study, there was a trade-off between anatomical coverage and Kaplan-Meier analysis, chemotherapy patients, for SUV max and washout curve shape with overall survival. SUV max , maximum standardized uptake value. Table 4 Change of PET/CT and DCE-MRI parameters posttreatment compared for patients with disease progression and progression-free at 7-9 weeks post-trial commencement CT, computed tomography; DCE, dynamic contrast-enhanced; IAUC90, integrated area under the first 90s of the curve; MTV, metabolic tumour volume; OS, overall survival; PFS, progression-free survival; SUV max , maximum standardized uptake value; SUV, standardized uptake value; TLG, total lesion glycolysis. CT, computed tomography; DCE, dynamic contrast-enhanced; IAUC90, integrated area under the first 90s of the curve; MTV, metabolic tumour volume; OS, overall survival; PFS, progression-free survival; SUV max , maximum standardized uptake value; SUV, standardized uptake value; TLG, total lesion glycolysis. temporal resolution. Dynamic sequences were acquired for up to 12 min in order to assess washout, but shorter frame times would be better for analysis of initial enhancement.
Quantification of DCE-MRI has only occasionally been carried out in MPM. One reason may be the complexity of the pharmacokinetic approach. We have shown that it is possible to derive measurements from DCE-MRI without specialised software or acquisition parameters. Simple curve-based measurements from DCE-MRI have been shown to be related to pharmacokinetic measurements, which can be generated from model-based analysis [25] , whereas pharmacokinetic measurements have been shown to be correlated with microvascular density in MPM [7] .
The SWAMP study recruited patients from seven centres. However, PET/CT imaging was only available at one centre, so all PET and MRI was carried out there. This created issues for recruitment and follow-up imaging, owing to the poor health of the participants and the distance from some recruiting centres. There were also some issues with archiving of image data, particularly for DCE-MRI. There were still sufficient numbers for analysis, but subgroup analysis, for example by histology, was more difficult. In the MRI studies, owing to the fairly long frame length used (45-55 s), information may have been lost about initial enhancement, although this should not have affected the analysis used of initial area under curve and washout slope significantly. The MRI studies were carried out on a 1-T scanner, and a more modern 3T scanner would be able to image the lungs with a shorter frame time. Owing to underlying disease, breath-holding was difficult, and thus the bases of the lungs particularly were affected by movement. Other semiquantitative measures for DCE-MRI have been proposed, including pharmacokinetic analysis, and it is possible that different methodology might make a difference. Alternatively, perfusion could be assessed by using contrast-enhanced CT, which could be carried out as part of the PET/CT study. It would be of interest to compare the results of perfusion assessment from CT and DCE-MRI in these patients. MRI will often be used as part of the diagnostic or patient management pathway, and in this case it might be appropriate to include assessment of DCE-MRI.
Conclusion
We have demonstrated that 18 F-FDG PET/CT and DCE-MRI can be quantified using relatively simple methods in a clinical setting, and that DCE-MRI carried out before treatment may offer prognostic information additional to that from 18 F-FDG PET/CT. Baseline measurements of SUV max , MTV and TLG from 18 F-FDG PET/CT were significantly related to OS. Baseline washout curve shape from DCE-MRI was significantly related to OS, and offered additional prognostic information when combined with PET/CT, although the PET/CT result was more clinically significant. No measurements of change after treatment from 18 F-FDG PET/CT or DCE-MRI were related to progression-free survival, and thus PET/CT and DCE-MRI are not recommended for follow-up in MPM.
PET/CT gives prognostic information in MPM. DCE-MRI gives some prognostic information, but PET/CT should be used instead of DCE-MRI where available.
